Servier to Acquire Day One Biopharmaceuticals for $2.5B

Suresnes, France & Brisbane, CA, March 6, 2026 (Globe Newswire) -- Servier has agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The acquisition strengthens Servier’s rare oncology portfolio, particularly in pediatric low-grade glioma, and adds several oncology programs spanning early development through Phase 3. The transaction, expected to close in the second quarter of 2026, combines Day One’s targeted therapy expertise with Servier’s global oncology capabilities to accelerate development of treatments for cancers with high unmet medical need.

Read full article here.